Treatment Guidelines from The Medical Letter
FROM
ISSUE
105
Drugs for Treatment of ADHD
The full article is available to subscribers Subscriber Login   
Read our blog post on this topic

Revised 4/1/14: The Daily Adult Dosages for Focalin and generic methylphenidate in Table 1 have been updated.

Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in about 5% of school-age children, most often in boys, and frequently persists into young adulthood.1,2

The drugs approved for treatment of ADHD by the FDA are listed in Table 1 on page 24. Except for atomoxetine, guanfacine and clonidine, they are all stimulants and are classified as Schedule II controlled substances by the US Drug Enforcement Administration (DEA). They are all approved for use in school-age children and adolescents, and most are approved for use in adults as well.

Professional medical associations such as the American Academy of Child and Adolescent Psychiatry have recommended trying other treatments in children less than 6 years old, such as an effective form of parent training, before resorting to stimulants. Stimulants can cause irritability and social withdrawal ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Treatment of ADHD
Article code: 105a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian